GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: This is one of the NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors claimed in patent WO2024240153 (Insilico Medicine Ip Limited) [1]. Insilico Medicine have announced development of an orally bioavailable, brain-penetrant NLRP3 inhibitor, named ISM8969, to target inflammatory diseases, including neurodegenerative inflammation in the CNS. The chemical structure for ISM8969 has not been declared (August 2025).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Wu J, Qin L, Ding X, Li C. (2024)
NLRP3 inflammasome inhibitors and uses thereof. Patent number: WO2024240153A1. Assignee: Insilico Medicine Ip Limited. Priority date: 21/05/2024. Publication date: 28/11/2024. |